利福霉素 O，一种可供选择的抗结核药物。
Rifamycin O, An Alternative Anti- Agent.
机构信息
Molecular Mechanisms of Antibiotics, Division of Life Science, Research Institute of Life Science, Gyeongsang National University, Jinju 52828, Korea.
Division of Applied Life Science (BK21plus Program), Gyeongsang National University, Jinju 52828, Korea.
出版信息
Molecules. 2020 Mar 31;25(7):1597. doi: 10.3390/molecules25071597.
Abstract
is the most difficult-to-treat nontuberculous mycobacteria because of its resistance to many antibiotics. In this study, we screened the Korea Chemical Bank library for a bioluminescent reporter assay to identify molecules capable of acting against On application of the assay, rifamycin O showed excellent in vitro activity with a narrow range of the minimum inhibitory concentration required to inhibit the growth of 90% of the bacterium (MIC = 4.0-6.2 μM); its in vivo efficacy in the zebrafish () infection model was comparable to that of rifabutin at 25 μM. Furthermore, rifamycin O did not show significant toxicity in cells and the zebrafish model. These results are the first in vivo indication that rifamycin O may be a drug candidate for treating infections.
摘要
是最难治疗的非结核分枝杆菌，因为它对许多抗生素具有耐药性。在这项研究中，我们筛选了韩国化学银行文库中的生物发光报告测定法，以鉴定能够对抗的分子。在应用该测定法时，利福霉素 O 表现出优异的体外活性，其抑制 90%细菌生长所需的最小抑菌浓度范围很窄（MIC = 4.0-6.2 μM）；其在斑马鱼（）感染模型中的体内疗效与 25 μM 的利福布汀相当。此外，利福霉素 O 在细胞和斑马鱼模型中没有显示出显著的毒性。这些结果首次在体内表明，利福霉素 O 可能是治疗 感染的候选药物。
相似文献
1
Rifamycin O, An Alternative Anti- Agent.利福霉素 O，一种可供选择的抗结核药物。
Molecules. 2020 Mar 31;25(7):1597. doi: 10.3390/molecules25071597.
2
Rifabutin Is Active against Mycobacterium abscessus in Mice.利福布汀对小鼠中的脓肿分枝杆菌有效。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01943-19.
3
Thiostrepton: A Novel Therapeutic Drug Candidate for Infection.硫链丝菌素：一种新型抗感染治疗候选药物。
Molecules. 2019 Dec 10;24(24):4511. doi: 10.3390/molecules24244511.
4
Blocking Bacterial Naphthohydroquinone Oxidation and ADP-Ribosylation Improves Activity of Rifamycins against Mycobacterium abscessus.阻断细菌萘氢醌氧化和 ADP-核糖基化可提高利福霉素类药物对脓肿分枝杆菌的活性。
Antimicrob Agents Chemother. 2021 Aug 17;65(9):e0097821. doi: 10.1128/AAC.00978-21.
5
Repositioning rifamycins for Mycobacterium abscessus lung disease.重新定位利福霉素类药物治疗脓肿分枝杆菌肺病。
Expert Opin Drug Discov. 2019 Sep;14(9):867-878. doi: 10.1080/17460441.2019.1629414. Epub 2019 Jun 14.
6
Redesign of Rifamycin Antibiotics to Overcome ADP-Ribosylation-Mediated Resistance.重新设计利福霉素抗生素以克服 ADP-核糖基化介导的耐药性。
Angew Chem Int Ed Engl. 2022 Nov 7;61(45):e202211498. doi: 10.1002/anie.202211498. Epub 2022 Oct 12.
7
Rifabutin Is Bactericidal against Intracellular and Extracellular Forms of Mycobacterium abscessus.利福布汀对脓肿分枝杆菌的细胞内和细胞外形式均具有杀菌作用。
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.00363-20.
8
Synergism of Rifabutin with Clarithromycin, Imipenem, and Tigecycline against the Complex.利福布汀与克拉霉素、亚胺培南和替加环素联合应用对复合体的协同作用。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02234-18. Print 2019 Apr.
9
Select β-Lactam Combinations Exhibit Synergy against .选择β-内酰胺类抗生素联合用药具有协同作用。
Antimicrob Agents Chemother. 2019 Mar 27;63(4). doi: 10.1128/AAC.02613-18. Print 2019 Apr.
10
Activity of Oritavancin and Its Synergy with Other Antibiotics against Infection In Vitro and In Vivo.奥他万星及其与其他抗生素协同作用的体外和体内抗感染活性。
Int J Mol Sci. 2021 Jun 14;22(12):6346. doi: 10.3390/ijms22126346.
引用本文的文献
1
Identification of a Drug Candidate against Using Pandemic Response Box.利用大流行应对箱鉴定一种抗……的候选药物
J Microbiol Biotechnol. 2025 Aug 18;35:e2506006. doi: 10.4014/jmb.2506.06006.
2
Antimicrobial and Antibiofilm Effects of Bithionol against .硫双二氯酚对……的抗菌和抗生物膜作用
Antibiotics (Basel). 2024 Jun 5;13(6):529. doi: 10.3390/antibiotics13060529.
3
Exploring antibiotic resistance mechanisms in for enhanced therapeutic approaches.探索[具体对象]中的抗生素耐药机制以改进治疗方法。 （你提供的原文“Exploring antibiotic resistance mechanisms in for enhanced therapeutic approaches.”中“in for”之间缺少具体内容，我根据语境补充了“[具体对象]”，你可根据实际情况调整）
Front Microbiol. 2024 Feb 6;15:1331508. doi: 10.3389/fmicb.2024.1331508. eCollection 2024.
4
CRISPR Interference-Based Inhibition of MAB_0055c Expression Alters Drug Sensitivity in Mycobacterium abscessus.基于 CRISPR 干扰的 MAB_0055c 表达抑制改变了脓肿分枝杆菌中的药物敏感性。
Microbiol Spectr. 2023 Jun 15;11(3):e0063123. doi: 10.1128/spectrum.00631-23. Epub 2023 May 9.
5
Omadacycline Potentiates Clarithromycin Activity Against .奥马环素增强克拉霉素对……的活性。 （原文结尾不完整）
Front Pharmacol. 2021 Dec 8;12:790767. doi: 10.3389/fphar.2021.790767. eCollection 2021.
6
Looking Back to : History of the Antibiotic Discovery and Future Prospects.回首往昔：抗生素发现史与未来展望。
Antibiotics (Basel). 2021 Oct 15;10(10):1254. doi: 10.3390/antibiotics10101254.
7
Current Molecular Therapeutic Agents and Drug Candidates for .当前用于……的分子治疗剂和候选药物
Front Pharmacol. 2021 Aug 30;12:724725. doi: 10.3389/fphar.2021.724725. eCollection 2021.
8
A Screening of the MMV Pandemic Response Box Reveals Epetraborole as a New Potent Inhibitor against .MMV 大流行应对工具箱的筛选显示埃泼司他硼是一种针对. 的新型有效抑制剂。
Int J Mol Sci. 2021 May 31;22(11):5936. doi: 10.3390/ijms22115936.
9
Etamycin as a Novel Inhibitor.依替米星作为一种新型抑制剂。
Int J Mol Sci. 2020 Sep 21;21(18):6908. doi: 10.3390/ijms21186908.
本文引用的文献
1
Thiostrepton: A Novel Therapeutic Drug Candidate for Infection.硫链丝菌素：一种新型抗感染治疗候选药物。
Molecules. 2019 Dec 10;24(24):4511. doi: 10.3390/molecules24244511.
2
Rifabutin Is Active against Mycobacterium abscessus in Mice.利福布汀对小鼠中的脓肿分枝杆菌有效。
Antimicrob Agents Chemother. 2020 Jan 27;64(2). doi: 10.1128/AAC.01943-19.
3
Rifamycin derivatives active against pathogenic rapidly-growing mycobacteria.抗致病性快速生长分枝杆菌的利福霉素衍生物。
Bioorg Med Chem Lett. 2019 Aug 15;29(16):2112-2115. doi: 10.1016/j.bmcl.2019.07.001. Epub 2019 Jul 2.
4
Repositioning rifamycins for Mycobacterium abscessus lung disease.重新定位利福霉素类药物治疗脓肿分枝杆菌肺病。
Expert Opin Drug Discov. 2019 Sep;14(9):867-878. doi: 10.1080/17460441.2019.1629414. Epub 2019 Jun 14.
5
: Shapeshifter of the Mycobacterial World.分枝杆菌世界的变形者。
Front Microbiol. 2018 Nov 1;9:2642. doi: 10.3389/fmicb.2018.02642. eCollection 2018.
6
Pathogen Box screening for hit identification against Mycobacterium abscessus.针对脓肿分枝杆菌的命中鉴定进行病原体盒筛选。
PLoS One. 2018 Apr 26;13(4):e0195595. doi: 10.1371/journal.pone.0195595. eCollection 2018.
7
Reporter-Based Assays for High-Throughput Drug Screening against .基于报告基因的高通量药物筛选检测方法 针对……
Front Microbiol. 2017 Nov 10;8:2204. doi: 10.3389/fmicb.2017.02204. eCollection 2017.
8
The Diverse Cellular and Animal Models to Decipher the Physiopathological Traits of Infection.用于解读感染生理病理特征的多种细胞和动物模型
Front Cell Infect Microbiol. 2017 Apr 4;7:100. doi: 10.3389/fcimb.2017.00100. eCollection 2017.
9
Rifabutin Is Active against Mycobacterium abscessus Complex.利福布汀对脓肿分枝杆菌复合群有活性。
Antimicrob Agents Chemother. 2017 May 24;61(6). doi: 10.1128/AAC.00155-17. Print 2017 Jun.
10
Intrinsic rifamycin resistance of Mycobacterium abscessus is mediated by ADP-ribosyltransferase MAB_0591.分枝杆菌属脓肿内在的利福霉素耐药性是由 ADP-核糖基转移酶 MAB_0591 介导的。
J Antimicrob Chemother. 2017 Feb;72(2):376-384. doi: 10.1093/jac/dkw466. Epub 2016 Dec 20.
Zotero 插件